Japanese JSR expands its biomedical business buy acquiring shares in BIA Separations, an Austrian downstream processing and separations specialist. The company is especially interested in BIA's biomolecule downstream technology, speakers said.
Tokyo/Japan – JSR boost its biomedical business by an investment in BIA Separations. Now the two firms team up for a joint global marketing and sales effort and collaborative. Also R&D activities for downstream purification technologies for the production of vaccine, DNA and antibody based medicines are expected to profit from this development.
This investments opens the doors for JSR to profit from BIA Separation's biomolecule downstream technology, company speakers said. JSR hopes to combine these technologies with its own protein A media for an even aster, more reliable downstream purification process with comparably low cost of ownership.